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Autoimmune-rheumatological diseases are worldwide distributed disorders and represent a
complex array of illnesses characterized by autoreactivity (reactivity against self-antigens) of
T-B lymphocytes and by the synthesis of autoantibodies crucial for diagnosis (biomarkers).
Yet, the effects of the autoimmune chronic inflammation on the infiltrated tissues and organs
generally lead to profound tissue and organ damage with loss of function (i.e., lung, kidney,
joints, exocrine glands). Although progresses have been made on the knowledge of these
disorders, much still remains to be investigated on their pathogenesis and identification of
new biomarkers useful in clinical practice. The rationale of using proteomics in autoimmune-
rheumatological diseases has been the unmet need to collect, from biological fluids that are
easily obtainable, a summary of the final biochemical events that represent the effects of the
interplay between immune cells, mesenchymal cells and endothelial cells. Proteomic analysis
of these fluids shows encouraging results and in this review, we addressed four major
autoimmune-rheumatological diseases investigated through proteomic techniques and
provide evidence-based data on the highlights obtained in systemic sclerosis, primary and
secondary Sjogren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis.
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1 Introduction
Autoimmune-rheumatological disorders group includes
Sjogren’s syndrome (SS), systemic sclerosis (SSc), rheu-
mathoid arthritis (RA), systemic lupus erythematosus (SLE),
spondyloarthritis, dermatomyositis and vasculitides [1–4].
The autoimmune-rheumatological disorders are distributed
worldwide with high social-economical impact (1% of the
population), in particular women with a 3/1 gender ratio
[3, 5, 6]. Previous studies on the pathogenesis of these
disorders have shown that the cumulative effects of multiple
environmental factors such as viral or bacterial infections and
toxic agents in genetic predisposed hosts lead to the produc-
tion of auto-reactive cellular and humoral immune responses
against self-systems, which are responsible for acute and
chronic organ damage, invalidating the patients and affecting
their life-style (Fig. 1) [4, 7]. Although progresses have been
made in the analysis of the pathogenesis of these disorders, a
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limited numbers of tools for clinical management and diag-
nosis are available until now.
The recent development of proteomic technologies for
massive protein analysis has facilitated the study of biolo-
gical fluids to identify potential new biomarkers useful for
early diagnosis, clinical management and evaluation of
treatments efficacy [8, 9]. The easier and less invasive
available biological fluids are serum, plasma, urine, saliva,
tears and bronchoalveolar lavage fluid (BALF) that contain
an enormous amount of proteins or peptides involved in the
regulation of different systems and possibly involved in the
pathogenesis of these autoimmune-rheumatological disor-
ders.
In the present review, we discuss the more significant
proteomic studies on biological fluids in autoimmune-
rheumatological disorders focusing on SS, SSc, RA and SLE
(Table 1).
2 Proteomic studies in SS patients
SS is a chronic, inflammatory, autoimmune disease char-
acterized by lymphocytic infiltration of the exocrine glands
leading to either qualitatively altered and reduced secretion
or absent glandular secretion, and by marked a B-cell
hyperreactivity with (i) hypergammaglobulinemia and (ii)
various serum autoantibodies such as the Abs against the
Ro(SSA) and La(SSB) ribonucleoproteins, the rheumatoid
factor, anti-a-fodrin (a cytoskeleton protein) and anti-M3R
[10]. In addition, a possible severe complication is the
development of B-cell lymphomas of the mucosa-associated
lymphoid tissue (MALT) type [10]. Clinical presentation of
SS disease is generally characterized by dry eyes (xeroph-
thalmia) with possible associated keratoconjunctivitis sicca
and dry mouth (xerostomia). SS disease may arise alone as
primary SS (pSS) or as secondary SS (sSS) disorder in
association with other well-established rheumatic disease as
RA or SLE [10]. However, approximately 40% of the patients
develop extraglandular manifestation as neurological,
pulmonary and complications within the clinical follow-up
Figure 1. Schematic representation of the pathogenesis of the
discussed autoimmune-rheumatological disorders: SS, SSc, RA
and SLE. The cumulative effects of multiple environmental
factors as viral or bacterial infections and toxic agents in genetic
predisposed hosts lead to the production of auto-reactive cellu-
lar and humoral immune responses against self-systems, which
are responsible for acute and chronic organ damage, invalidat-
ing the patients and affecting their life-style.
Table 1. Proteomic studies of biological fluids from patients with autoimmune-rheumathological disorders
Biological markers
used in clinical
practice
Possible biomarkers for future use in clinical practice Biological
fluid analyzed
References
pSS Anti-SSA/Ro Ab b2-Microglobulin, Cystatin C, Cystatin A, Actin, defensin-1,
b-defensin-2, calgranulin B, albumin
Saliva [15–21]
Anti-SSB/ La Ab,
complement C3, C4
Tears
SSc Anti-ACA SSA protein, complement factor H, mtDNAtopo 1, calgranulin B,
Thymosins b Psoriasin S100, calgranulin A and B
Serum [41–49, 53, 54]
Anti-estractable nuclear BALF
Antigen-Scl70 Ab Saliva
RA RF CTL1; chain A of transthyretin, SSA, Apo IV, haptoglobin,
Cp, Ig superfamily 22; Ig: immunoglobulin, CRP,
cathepsin D, Thymosin b4
Serum [61, 63, 66–69,
74–78]Anti-CCP Abs, anti-MCV Plasma
SLE Anti-dsDNA Abs INA Abs, I-IFN, transferrin, a1-acid-glycoprotein and
lipocalin-type prostaglandin D-synthetase, hepcidin 20
Plasma [84, 85, 87, 88,
90–93, 99]Complement C3,C4 Urine serum
pSS, primary Sjogren’s syndrome; SSc, systemic sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; Ab, antibody;
anti-SSA Ab, autoantibodies agains epitopes on polypeptides associated with small RNAs called scYRNA situated mostly in the
cytoplasmic compartment (70%) and few in the nuclear compartement (30%); anti-CCP Abs, antibodies to cyclic citrullinated protein; anti-
dsDNA Abs, anti-nuclear antibodies; SSA protein, amyloid serum protein; CTL1, coactosin-like 1; Apo IV, apolipoprotein IV; Cp,
cerulopasmin; ACA, anticentromere antibodies; INA Abs, anti-intermediate neurofilament a-intermexin; RF, rheumatoid factor; CRP,
C-reactive protein; antiMCV, anti-mutated citrullinated vimentin antibodies.
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[10]. SS prevalence is approximately 0.1–0.6% of the adult
population [11].
Since the characteristic involvement of salivary and
lachrymal glands in SS patients is clinically evident as
xerostomia and xerophthalmia, the proteomic analysis of
biological fluids as saliva or tears is important to identify
new biomarkers involved in the pathogenesis of the disease
and/or useful in clinical management of SS patients. In
addition, saliva and tears are relatively simple biological
fluids to collect and can mirror local and systemic patholo-
gical changes related to SS disease [8, 12].
Although studies on human salivary proteome in healthy
subjects have been reported, much still remains to be
investigated on the dynamic changes in saliva proteome
among subjects, within the day in the same subject, among
different salivary glands, and between salivary glands and
crevicular fluid [13, 14].
Studies in SS patients have shown that xerostomia and
xerophthalmia result from a loss of exocrine cell mass
associated with neural dysregulation of glandular secretion
due to the combination of the following factors: epithelial
cells apoptosis, production of functional antagonistic auto-
antibodies as anti-M3R and infiltrating effector T cells [10].
However, the reduced tear and saliva flow rates are also
associated with changes in their protein composition; thus,
the proteomic analysis of these biological liquids represents
an interesting tool in biomarker discovery [15]. In a litera-
ture review, we found five studies that investigated the saliva
proteome from SS patients compared to normal controls
[16–20], two studies investigated the compositions of tears
from SS patients [15, 21], but none simultaneously evaluated
saliva and tear proteome from the same SS patients.
Table 2 summarizes the more relevant information on
the proteomic analysis of saliva from SS patients. All studies
were carried out in pSS subjects compared to normal
controls. In four studies, whole saliva proteome was
analyzed and in 2 out of 5 studies, the authors have eval-
uated saliva from parotid glands, even though Hu et al. have
Table 2. Proteomic studies of saliva from SS patients
Ryu HO et al.
[16]
Giusti L et al.
[17]
Peluso et al.
[18]
Hu et al. [19] Fleissig et al. [20]
Proteomic
Approach
2-D DIGE 2-DE HPLC 2-DE 2-DE
SELDI-TOF MALDI-TOF ESI MALDI-TOF ESI-MS/MS
LC-MS/MS microarray
Patients 41 Primary SS 12 Primary SS 9 Primary SS 10 Primary SS 6 Primary SS
Controls 15 Dry mouth 5
healthy
12 Healthy 10 Healthy 10 Healthy 8 Healthy
Biological liquid Parotid saliva Whole saliva Whole saliva Whole saliva Whole saliva
Parotid saliva
Submandibular/lingual
Sample
collection
time
2 h after breakfast Before
breakfast
2 h after lunch 2 h breakfast After 1 h since the
last meal
Saliva
stimulation
Citric acid None None pilocarpine Chewing paraffin None
Biomarkers:
down-
regulated
proteins
PRP Amylase,
Carbonic
anhydrase VI
a-Amylase pr,
Cystatin SN
pr, Keratin
6-L, PIP
PF, IB-8a, IB-1, desR, II-2,
desR, PRP1, 3, PC,
desRPQ Statherin, 1P,
desD1, SV2, des1-9,
des1-10, P-B, des1-4
Cystatin C, S, S1, S2,
SA, SN, histatin1-12
Carbonic anhydrase VI,
Polymeric Ig R,
Lysozyme C, Prolactin-
inducible p, Von
Ebner’s gland p,
Cystatin C, SN, D, S,
SA, Calgranulin A
Polymeric Ig R,
Vitamin D binding
p, a-amylase
Biomarkers: up-
regulated
proteins
b2-Microglobulin,
Lactoferrin, Ig
K light chain,
Polymeric Ig R,
Lysozyme C,
Cystatin C
E-FABP, Actin,
b-actin f,
Leukocyte
elastase
inhibitor,
GST, 5 not
identified
proteins
PB des1-4, Cystatin A,
a-defensin-1, b-
defensin-2
Calgranulin B, Psoriasin,
Hemoglobin a, b chain,
E-FABP, IGHG1, IGHM,
a –enolase, a-amylase f,
Fructose-bisphosphate
aldolase A, Ig g1-chain
C-region, Carbonic
anhydrase I, II, Caspase
14, Ig k-chain C-region,
b2 microglobulin, Actin,
Albumin f
Keratin I, II, Albumin,
Actin, Fibrinogen
b chain, Ig g1-
chain C-region,
Calgranulin B,
Calcium binding p
pr: precursor; Ig: immunoglobulin; R: receptor; p: protein; f: fragment; PIP: prolactine inducible protein; FABP: fatty acid binding protein;
GST: glutathione S-transferase; IGHG: immunoglobulin heavy chain igG; IGHM: immunoglobulin heavy chain igM.
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also analyzed saliva from submandibular and sublingual
glands [19]. In these studies, the samples were collected
after different time intervals, after breakfast or lunch, and in
two studies a known saliva stimulator such as citric acid or
chewing paraffin was used [16–20].
In SS patients, the proteomic data show that proteins of
acinar origin, such as proline-rich proteins, histatins, and
statherin, were reduced, while inflammatory acute-phase
proteins, such as lactoferrin, fibrinogen and albumin, were
increased compared to normal subjects [16–20]. Some
proteins that were either two- to three-fold up- or down-
regulated in SS patients compared to normal controls or
exclusively present in SS saliva have been indicated as
possible pSS biomarkers (Table 2). It is of interest to note
that defensins, a class of immune-peptides involved in the
innate immunity against bacteria and fungi, were found to
be biomarkers of SS, being up-regulated in both saliva and
tears from SS patients [18, 20, 22].
a and b defensins are a family of small cationic proteins,
3000–4000Da, involved not only in the innate immune
system against infectious microbes but also in adaptive
immunity, inflammation and wound repair [13]. a-Defen-
sins 1–4 are present in granules of neutrophils [13].
Recently, the presence of a-defensins 1–3 in saliva from
normal subjects and low levels of a-defensin-4 in gingival in
crevicular fluid from normal subjects has been detected by
HPLC-ESI-MS [14]. In whole saliva from SS with both pSS
and sSS form, Peluso et al. have reported increased
a-defensin-1 levels in pSS patients compared to either
normal controls or sSS subjects [18]. Since defensins play an
important role in modulation of local anti-inflammatory
response, we have proposed the increased amount of
a-defensin-1 in pSS patients as result of periodontal disease
that is common in pSS patients, suggesting a possible role
of a-defensin-1 as a marker of oral inflammation in pSS
patients [18].
b-Defensins 1–2 are mainly expressed by keratinocytes
[23]. b-Defensin-1 is constitutively and heterogeneously
expressed in epithelial cells and only poorly induced by
cytokines. Otherwise, b-defensins-2 can be induced by local
cytokine imbalance once a predominance of Th1 lymphocytes
related cytokines such as the tumor necrosis factor-a, simi-
larly to what observed in other oral inflammatory or infec-
tious diseases [24]. Kawasaki et al. have reported a significant
up-regulation of only b-defensin-2 gene in conjunctival
epithelial cells from pSS patients [22]. Recently, we have
found b-defensin-2 in saliva from pSS patients but not in
healthy subjects, suggesting b-defensin-2 as marker of pro-
inflammatory response in pSS patients, most likely related to
the high levels of local cytokines such as TNFa [18, 25, 26].
The association of SS with marginal zone B-cell
lymphomas is present in up to 5% of SS patients [27]. The
salivary extranodal marginal zone B-cell lymphomas of
MALT type are the most common lymphomas in SS [27].
Hu et al. have performed a transcriptomic and proteomic
analysis of human parotid glands from patients with
either pSS alone or associated with MALT lymphoma [28].
The authors proposed a panel of eight candidate
genes (GRB2, ARHGDIB, CD40, proteasome subunit,
aldolase A, peroxiredoxin 5, PARC, cyclophilin A) to
distinguish pSS from pSS associated MALT form [28].
However, the clinical application of these markers is extre-
mely limited and it would be of interest to carry out an
integrated genomic and proteomic analysis of saliva and
glandular tissues from these patients to validate the identi-
fied biomarkers [29].
However, the proteomic studies on saliva from SS
patients still indicate the following: (i) the importance to
develop a uniform protocol to collect saliva; (ii) the whole
saliva as the more informative sample in SS patients
compared to single gland-derived saliva; (iii) integration of
different MS techniques to study low-molecular-weight
proteins [30, 31].
3 Proteomic studies in SSc subjects
SSc is a multi-organ connective tissue disease characterized
by microvascular abnormalities associated with skin and
internal organ fibrosis. SSc prevalence is approximately
0.001–0.004 % of the adult population [7, 32]. To date, no
effective treatment is available, probably because the etio-
pathogenesis of SSc is not completely clarified. SSc is
characterized by three hallmarks: microvascular abnormal-
ities, autoimmune system activation and tissue fibrosis [33].
It seems that the primary event in the pathogenesis of the
disease is the endothelial cell (EC) damage with infiltration
of mononuclear inflammatory cells and increased extra-
cellular collagen deposition [34]. Several evidence suggests
that environmental agents lead to the production of an
autoimmune response in a genetically predisposed host, but
the cause of the higher host susceptibility remains to be
discovered. Abs against different cellular and intracellular
antigens are detected in 80–90% of serum from SSc
patients; autoantibodies to several nuclear and nucleolar
antigens or other autoantobodies such as anti-EC Abs
(Table 1). It has been shown that anti-EC Abs are capable of
promoting the leukocyte adhesion to ECs and also of indu-
cing the death of these cells. Other hypothesis, not mutually
exclusive, suggests that oxygen-free radicals and cytokines
may play a central role in the pathogenesis of SSc. The
reactive oxygen species produced during chronic inflam-
matory response, further amplify the vascular damage in
SSc patients, resulting in EC dysfunction and fibroblast
proliferation [35]. In addition, the transforming growth
factor-b and the connective tissue growth factor activate
fibroblasts and contribute to fibrosis by increasing the
extracellular matrix deposition [36].
In SSc patients, the lung involvement is the leading
cause of morbidity and mortality [37], but the variability of
lung damage and the rate of progression vary between SSc
patients. The BALF analysis is essential to diagnose alveo-
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litis that characterize a subset of SSc patients [37–39]. Thus,
BALF analysis is actually considered a suitable method just
to evaluate the presence of lower respiratory tract infections
in clinical setting or to obtain material for research purposes
[40, 41].
Several papers on proteomic analysis of BALF, saliva and
serum in SSc patients have been recently reported [41–48],
allowing an insight on proteins that are potentially crucial to
the biology and the development of fibrotic and vascular
damage in SSc subjects (Table 1).
4 BALF and saliva proteomic studies in
SSc patients
To date, the studies on BALF proteome in SSc are not
conclusive in demonstrating a SSc-specific protein pattern
[41–44]. Rottoli et al. have conducted a 2-D analysis of BALF
from SSc patients with interstitial lung disease (ILD)
[41, 42]. The authors have reported quantitative rather than
qualitative differences in protein profile in the comparison
between SSc patients with lung involvement and patients
with other ILD forms, such as idiopathic pulmonary fibrosis
or sarcoidosis [41]. The differently expressed proteins belong
to the classes of proteases/antiproteases, coagulation
system, cytokines, antioxidant proteins and calcium binding
proteins. The study highlighted that plasma-derived and
locally produced proteins have intermediate levels in BALF
from SSc subjects when compared to that from patients
with sarcoidosis or idiopathic pulmonary fibrosis.
In another study, Fietta AM et al. compared BALF from
SSc patients with and without lung disease by 2-D with
MALDI-TOF and HPLC-MS analysis [43]. The authors
found nine differently expressed proteins in BALF. Among
these proteins, a fragment of mtDNAtopo 1 was found only
in BALF from SSc patients with ILD, while glutathione
S-transferase P and cystatin SN were detectable only in SSc
patients without lung disease. In addition, increased levels
of calgranulin B, a molecule promoting extracellular matrix
deposition and lung fibrosis [44], were found in BALF from
SSc patients with ILD compared to SSc patients without
lung involvement, similarly to what observed in BALF from
patients with idiopathic pulmonary fibrosis [41–44]. The
major limitation of these studies are (i) the small number of
patients, (ii) the absence of control subjects and (iii) the lack
of sensitivity of 2-D MALDI-TOF approach in identifying
low molecular weight proteins. We have recently reported
preliminary data on BALF from SSc patients, using reverse
phase-HPLC coupled to a quadrupole ion-trap MS via an
ESI analysis to identify small proteins and peptides and we
found thymosins b in BALF from SSc subjects [49].
Thymosins b are peptides involved in cytoskeleton rearran-
gement and transcription of signaling molecules [50]. Since
recent studies have indicated a functional role of these
peptides in angiogenesis, fibrosis and reparative process
[51, 52], the identification of b thymosins in BALF from SSc
patients might suggest their possible involvement in the
pathogenesis of SSc disease. In fact, we found increased
levels of thymosin b4 in SSc patients with ILD and inter-
estingly, the sulfoxidated form of thymosin b4, derived from
the oxidation of a methionine residue, was found to be a
possible biomarker of lung inflammation and oxidative
stress in our SSc cohort [49]. These data are in agreement
with a previous study reporting increased carbonylated
proteins in BALF from SSc patients as a marker of oxidative
and inflammatory damage in SSc lung [42].
A proteomic study on fibroblasts from BALF of patients
with SSc by 2-DE in combination with MS has been reported
[45]. In particular, 24 differently expressed protein spots had
been identified, including cytoskeletal proteins (such as
vimentin, tropomyosin and actin associated proteins) and
proteins involved in redox imbalance (such as disulfide
isomerase and glutathione S-transferase), which may
contribute to EC damage, fibroblast trafficking and inflam-
matory response in SSc patients [45]. In another study, on
saliva from SSc patients with a moderate–severe decrease of
diffusion lung capacity for carbon monoxide and with the
evidence of psoriasin has been described [48]. Psoriasin is a
member of S100 protein family and is a potent chemotactic
inflammatory protein for neutrophils and CD41
T lymphocytes, and it might be interesting to evaluate it in
other biological fluids from SSc patients to better under-
stand its possible role in the pathogenesis of this disorder.
Thus, the proteomic approach in the analysis of BALF or
saliva from SSc patients with lung involvement might help
to characterize the complex alveolar microenvironment,
which is important for insights into pathogenetic mechan-
isms of ILDs, and to identify groups of disease related
proteins including diagnostic and prognostic markers and
new targets of therapy.
5 Proteomic analysis of serum protein
profile from SSc patients
In sera from SSc patients, Brandwein et al. have reported
high levels of amyloid-related serum protein that is involved
in chemotaxis of inflammatory cells, modulation of proin-
flammatory cytokines and EC proliferation [53]. Recently, we
have carried out a comparative proteomic analysis of sera
from SSc patients and we identified 14 differentially
expressed proteins that are mainly involved in EC protection
and immune response [54]. In particular, we found
increased concentrations of complement factor H in SSc
subjects compared to healthy controls. Factor H is an
important regulator of the alternative complement pathway,
which normally protects self-cellular surface from comple-
ment cascade. Interestingly, we documented a defective
capacity of factor H to bind ECs and to protect them from
complement-mediated damage. An aberrant expression of
complement regulatory proteins has been already demon-
strated in the endothelium of patients with SSc and it has
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been suggested that an inadequate protection from
complement activation on cellular surface may be very
important in the early phase of SSc disease. In fact, the
recruitment of circulating fibroblasts progenitor cells and
their activation into the tissue are events that may be
facilitated by the microvascular dysfunction allowing the
development of fibrotic and vascular damage characteristic
of SSc disease [54, 55].
6 RA
RA is a chronic autoimmune inflammatory disease
primarily involving the diarthrodial joints, such as hands,
feet or knees [56]. However, the systemic nature of RA can
lead to the involvement of several organs (i.e., lungs, vessels,
nerves, bones) with the development of various comorbid-
ities [57]. Inflammation usually starts in the synovial
membrane where inflammatory-immune cells migrate from
vessels. The inflamed synovial tissue is a complex mix of
cells (fibroblasts, macrophages, lymphoid cells, dendritic
cells, mast cells) that invades and destroys the cartilage
through the synthesis of several cytokines and matrix
metalloproteinases, resulting in erosion and destruction of
the joints [57, 58]. RA prevalence rate is approximately
0.5–1% of the adult population [59, 60].
Proteomics have been used to define the biochemical/
immunological changes in serum plasma proteome and the
effects of biologic therapies (Table 3).
Liao et al. used 2-D LC-MS/MS in the analysis of synovial
fluid and serum protein profile from RA patients with and
without bone erosions [61]. In the more severe RA form,
associated with erosive disease, in synovial fluid they found
increased levels of C-reactive protein and calgranulin A, B, C
that are potent pro-inflammatory molecules with chemo-
tactic properties [62]. Recently, Jin et al. have reported the
protein expression profile of plasma and sera from RA
patients compared to healthy controls analyzed by 2-DE
followed by MALDI-TOF-MS. The comparative proteomic
analysis allowed the identification of 17 differently expres-
sed proteins mainly related to inflammatory response [63].
Between the identified proteins in sera from RA patients,
the authors focused on the small protein coactosin-like 1
that binds filamentous actin or 5-lipoxygenase, an enzyme
involved in leukotriene biosynthesis in leukocytes [64, 65].
The authors further found a significant association of the
c.484G4A polymorphism of protein coactosin-like 1 with
the levels of anti-cyclic citrullinated peptide Ab, a biomarker
used in diagnosis and clinical follow-up of RA patients,
suggesting a possible increased susceptibility of subjects
with protein coactosin-like 1 polymorphism for development
of RA [63].
Table 3. Proteomic studies on biological fluids from rheumatoid arthritis (RA) patients and effects of biological therapies
Rheumathoid arthritis
(RA)
Biological fluid
studied
Proteomic approach Differentially expressed proteins
Liao et al. 2004 Serum 2-D-LC-MS/MS C-reactive protein, calgranulin A, B, C
Synovial fluid
Jin et al. 2009 Serum
Plasma
2-DE & MALDI-TOF MS/
MS
COLT1, SAA1
Li et al. 2010 Serum
Long et al. 2010 Serum MB & MALDI-TOF MS 3 peaks at 2490; 5910.07; 6436.73 m/z
de Seney et al. 2005 Serum SELDI-TOF MS MRP-8
Serada et al. 2010 Serum iTRAQ-MS validated by
ELISA
LRG, actin, thymosin b, vimentin, tubulin, calgranulin
A, B, C
Zheng et al. 2009 Plasma RP-HPLC & Linear ion trap-
FT
CRP, SAA, Actin, Thymosin b4, Talin 1, Calgranulin
a,b,c
Goe¨b et al. 2009 Serum 2-DE & MALDI-TOF MS/
MS
FUSE-BP
Steendam et al. 2010 Serum Synovial
fluid
1/2-DE & LC-MS/MS Citrullinated fibrinogen b, citrullinated vimentin
RA and Infliximab
Dwivedi et al. 2009
Serum iTRAQ-LC-MS TNF-a and NF-kB related proteins, C-reactive protein
RA and Infliximab Plasma SELDI-TOF MS/MS PF4, Apolipoprotein
Trocme et al. 2009
RA and Infliximab Serum 2-DE-LC-MS/MS TNF-a and NF-kB related proteins
Sekigawa et al. 2008 Plasma
RA and Rituximab Serum PBAT C-reactive protein, IL-6
Fabre et al. 2009
PBAT: protein biochip array technology; COLT1: Coactosin like 1; SAA: serum amyloid protein; CRP: C reactive protein; FUSE-BP: far
upstream element-binding proteins PF4: Platelet factor 4; MCP-1: monocyte chemoattractant protein-1; EGF: epidermal growth factor; IL6:
interleukin 6; MRP8: myeloid related protein-8; ELISA: enzyme linked immunoassorbent assay.
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In another proteomic study, sera from RA patients were
studied by 2-D and MS analysis [66]. Eight proteins either
over or underexpressed in sera of RA patients were identi-
fied. Among them, chain A of transthyretin was under-
expressed, while serum amyloid A protein, apolipoprotein
A-IV, haptoglobin 2, ceruloplasmin, immunoglobulin
superfamily 22 and HT016 were over-expressed [66].
To study the low-abundant proteins in serum from
RA patients, Long et al. have analyzed profiling serum
proteins using magnetic bead-based separation followed by
MALDI-TOF-MS analysis [67]. A pattern based on three
mass/charge peaks (m/z 2490, 5910.07, 6436.73) discrimi-
nated patients with RA from healthy controls with a
sensitivity and specificity of 87.5 and 96.7%, suggesting
the possible use of this proteomic approach for early diag-
nosis of RA.
Using SELDI-TOF-MS to evaluate the low-molecular-
weight proteins, de Seny et al. [68] examined serum samples
from 34 RA patients compared to two control groups: a
group of patients with other inflammatory diseases, such
psoriatic arthritis or Crohn’s disease and a group of healthy
subjects. Two chip-arrays were used: CM10 as cation
exchange surface and H4 as hydrophobic surface. The most
discriminant mass/charge m/z peaks were highlighted: m/z
values of 2924 (RA versus controls on H4 arrays), 10 832 and
11 632 (RA versus controls on CM10 arrays). Based on these
evidences the 10 832 peak was considered as possible
myeloid related protein-8, which is up-regulated in different
autoimmune disorders and it has been shown to be func-
tionally connected with autoreactive lymphocytes [61, 69].
They validated their hypothesis by immunoblot analysis and
showed the association between the 10 832 peak and anti-
cyclic citrullinated peptide Ab in sera from RA patients,
supporting the proteomic analysis to identify possible
biomarkers of inflammatory diseases.
Goe¨b et al. used a different strategy to identify new
autoantibodies in early RA useful as new biomarkers in
clinical management. The authors analyzed serum protein
by immunoblot using HL-60 cell extract and identified by
MALDI-TOF approach. Phosphoglycerate kinase 1 and the
stress-induced phosphoprotein 1–2 were identified as new
antigens in sera from RA patients. Stress-induced phos-
phoprotein 1–2 is a trans actin protein that may stimulate
the promoter activity of the pro-oncogen c-myc, the expres-
sion of which has been shown to be increased in sinovial
tissue fibroblast from RA subjects. Thus, citrullination of
stress-induced phosphoprotein 1–2 through dysregulation of
c-myc might participate in RA synovial hyperplasia [70–73].
In addition, the authors suggest that autoantibodies recog-
nizing citrullinated peptide from stress-induced phospho-
protein 1–2 may increase the sensitivity of the currently
used anti-cyclic citrullinated peptide test [74].
Recently, van Steendam et al. have analyzed serum and
synovial fluid (SF) of RA patients compared to normal
controls. Protein analysis was carried out combining detec-
tion of citrullinated proteins by Western blot and protein
identification by LC-MS/MS. The authors showed that
citrullinated fibrinogen b and citrullinated vimentin were
the prominent citrullinated antigens in immunocomplex
from SF of RA patients with elevated levels of citrullinated
proteins, suggesting that citrullinated vimentin might play a
role in sustaining active RA [76].
Along the lane of distinguishing between RA patients
and controls, a quantitative proteomic approach that used
iTRAQ followed by MS analysis further validated by
enzyme-linked immunoassorbent assay showed that among
326 proteins identified by proteomic analysis, increased
serum levels of leucine-rich a-2 glycoprotein was present in
RA patients [75].
Relative differences in the protein classifications were
observed in RA human plasma samples compared with
controls: structural proteins, immuno-related proteins,
protease inhibitors, coagulation proteins, transport proteins
and apolipoproteins. While some of these proteins/peptides
have been previously reported to be associated with RA
disease such as calgranulin A, B, C and C-reactive protein,
several others were newly identified, such as thymosin 4,
actin, tubulin and vimentin [77].
The recent development of biological drug therapies
against known targets involved in inflammatory response
such as the monoclonal Ab against the tumor necrosis
factor-a (infliximab) or the chimeric monoclonal Ab against
the B lymphocytes surface protein CD20 (rituximab) has
dramatically changed the clinical management of RA
patients. Proteomic approaches have been used to find new
biological indicators of clinical response to these new
treatments possibly useful in clinical practice (Table 3,
grey area) [78–81]. Dwivedi et al. have analyzed serum
proteome from RA patients treated with infliximab after
depletion of the most abundant proteins followed by
labeling with iTRAQ to carry out a quantitative analysis [79].
They identified an average of 373 distinct proteins
per patient with greater than 95% confidence. In sera from 3
out of 10 RA patients studied, they found significant
changes in 39 serum proteins following the treatment. The
large part of these proteins were directly or indirectly
regulated by the tumor necrosis factor-a and nuclear factor-
B, with acute-phase proteins being uniformly down-regu-
lated. In another proteomic study, plasma from RA patients
treated with infliximab were analyzed by SELDI-TOF-MS
technology on two proteo-chip: SAX2 as anion exchange
surface and IMAC3-Ni, as nickel affinity array, combined
with biomarker characterization by either metal affinity
chromatography or ammonium sulfate precipitation
followed by MALDI-TOF analysis [80]. The authors identi-
fied six proteins as possible biomarkers and suggested
apolipoprotein A1 as predictive of positive response to
infliximab and platelet factor 4 as marker of RA non-
responders to infliximab.
Sekigawa et al. investigated by 2-D LC-MS/MS approach
sera and plasma from RA patients (n5 10) treated with
infliximab compared to normal controls [81]. They observed
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changes in protein expression related to tumor necrosis
factor-a and nuclear factor-kB similarly to Dwivedi et al. [79].
Proteomic analysis by proteo biochip array technology
was used to study the effects of rituximab on sera from
RA patients [78]. The authors found significantly higher
serum levels of pro-inflammatory cytokines, monocyte
chemoattractant protein-1 and epidermal growth factor in
responders than in non-responders RA patients and a
significant decrease of C-reactive protein and IL-6 levels
in the responder RA patients after 3 months of treatment
with rituximab, suggesting that the proteomic analysis
might be an interesting tool to identify biomarkers helpful
in discriminating responder from non-responder RA
patients.
These studies show that the analysis of serum plasma
despite the wide amount of proteins by proteomic approach
might allow the early diagnosis of complex autoimmune
diseases such as RA, the identification of biomarkers useful
for either clinical follow-up or identification of RA patients
responders to biological treatments.
7 SLE
SLE is a systemic autoimmune disease characterized by a
large variety of clinical manifestations associated with
autoantibodies against nuclear autoantigens as well as
cytoplasmic and circulating proteins (Table 1) [82]. These
autoantibodies in the presence of abnormally
activated acquired and innate immunity are responsible for
cytotoxic and immune complex-mediated organ damages
involving skin, kidney, brain, lung, joint and serosal tissues
[82, 83]. The prevalence of SLE is in the order of 20–100
cases per 100 000 individuals, but varies by gender,
ethnicity, socio-economic status, and genetic and environ-
mental backgrounds [82, 83]. Although various Abs and
different cytokines have been proposed for the pathogenesis
of SLE, their role in the disease remains often to be
elucidated.
Recently, Lu et al. have detected high titers of anti-
intermediate neurofilament a-intermexin Abs in serum and
cerebrospinal fluid of patients with neuropsychiatric
systemic-SLE, which seem to be very important in the
development of the disease [84]. In fact, they have demon-
strated that mice, previously immunized with recombinant
intermediate neurofilament a-intermexin, exhibit cognitive
deficits that raise neuropsychiatric systemic-SLE symptoms
and develop cortical lesions with related neuron apoptosis.
In another work, Bauer et al. have shown that interferon
regulates chemokine expression in serum of SLE patients
[85]. High levels of interferon had been already documented
in serum of SLE patients, especially in subjects with active
lupus [86]. Using immunoassay, the authors have identified
30 type I-interferon dysregulated proteins, whose levels
correlate with clinical and laboratory measures of disease
activity. This group of patients present up-regulated proteins
including cytokines IL-5, IL-6, IL-15, IL-18, brain derived
neurotrophic factor and glial cell line-derived neurotrophic
factor, cytokine receptors IL-2SRA and TGF-B-RIII, metallo-
proteinase 7 and adhesion molecule such as the intracellular
adhesion molecule-5. Down-regulated proteins have been
also documented, such as interferon-O, angiotensin
converting enzyme, chemokine CCL20, growth factor
FGF-2, growth factor receptors FGF-R3 and platelet-derived
growth factor type A receptor. Moreover, Li et al. have
highlighted Abs class-switch from IgM to the more patho-
genic IgG class in serum of SLE patients with high levels of
a-interferon [87].
Haptoglobin is another acute-phase protein that resulted
increased in plasma of SLE patients with high activity of
disease when compared with either healthy controls or SLE
patients with low SLEDAI clinical score of disease activity
(0–5). Increased levels of haptoglobin type 2-2 and hapto-
globin 2-1S and decreased levels of haptoglobin 2-1F are the
major peptide differences detected in plasma from these
patients by proteomic approach [88]. It has been postulated
that haptoglobin 2-2 phenotype is associated with increased
Abs production and lower hemoglobin-binding capacity that
may result in renal damage [89]. Proteomic analysis of urine
from SLE patients has also identified several biomarkers
with possible predictive power in disease flares. Suzuki et al.
have investigated the urinary protein profile in 32 paediatric
patients with SLE and 11 subjects with juvenile idiopathic
arthritis (JIA) [90]. They have not found significant differ-
ences between SLE patients without nephritis and JIA
patients, which have been used as controls since the JIA
patients have inflammatory joint involvement related to
autoimmune genesis but without the specific autoantibodies
and the clinical presentation of SLE (Table 1). Conversely,
they have detected eight protein spots significantly greater
expressed in subjects with lupus nephritis (LN) compared
with JIA controls and SLE patients without nephritis. By
MALDI-TOF-MS analysis, they identified these molecules as
transferrin, ceruloplasmin, a1-acid-glycoprotein, lipocalin-
type prostaglandin D-synthetase, albumin and albumin-
related fragments that strongly correlate with the renal SLE
disease activity. It is interesting to note that urinary levels of
transferrin, a1-acid-glycoprotein and lipocalin-type pros-
taglandin D-synthetase are increased few months before the
clinical presentation of renal damage [91]. Mosley et al. have
analyzed by SELDI-TOF-MS urine samples of 26 active LN
patients and have compared the results with the urinary
protein profile of 49 inactive LN subjects [92]. They have
found two protein ion peaks with m/z of 3340 and 3980 that
are strongly associated with active LN that could represent a
specific assay to monitor patients with renal disease without
invasive procedures, such as renal biopsies.
In a recent study, Zhang et al. have demonstrated that
hepcidin isoforms are differentially expressed in the urine of
SLE patients during a renal flare cycle [93]. In particular,
hepcidin 20 is increased 4 months before renal flare and
returned to baseline 4 months after the flare; hepcidin 25 is
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decreased at renal flare and returned to baseline 4 months
after the flare. Hepcidine is a small peptide that is involved
in the iron metabolism and is up-regulated during a chronic
inflammatory processes [94, 95]. Hepcidin expression is
regulated by IL-6 and tumor necrosis factor-a [96, 97] and
both cytokines are known to be involved in LN kidney
disease [98].
Finally, Varghese et al. have examined urine from of 32
patients with LN, focal segmental glomerulosclerosis,
membranous nephropathy or diabetic nephropathy, using
2-DE and MALDI-TOF/TOF or LTQ-Orbitrap MS analysis
[99]. They have identified 11 peptides that may be potential
urine biomarkers for the diagnosis of the major renal
diseases: orosomucoid, transferrin, a-1 microglobulin, zinc
a-2 glycoprotein, a-1 antitrypsin, complement factor B,
haptoglobin, transthyretin, plasma retinol binding protein,
albumin, and hemopexin. Moreover, they have generated
urine protein patterns for the most common glomerular
diseases by an artificial neural network analysis, but these
data must be validated in a larger cohort of patients and with
a more reproducible assay, as suggested by the authors
themselves.
8 Concluding remarks
High-throughput MS approaches coupled to different
separation techniques (i.e., HPLC and 2-D) have been used
to study various human fluids from patients with auto-
immune-rheumatologic diseases with the aim to enhance
our understanding of disease pathogenesis and to identify
biomarkers for non-invasive disease diagnosis, staging or
monitoring. Several factors make difficult to define a panel
of markers that can collectively enhance the sensitivity and
specificity for the non-invasive diagnosis of rheumatologic
diseases, such as SS, SSc alveolitis, RA or SLE. The most
important limits are (i) the lack of a comprehensive
proteomic analysis of saliva, BALF and urine of healthy
subjects; (ii) the lack of uniform protocols to collect and
prepare these samples for proteomic analysis; (iii) the high
grade of posttranslational modification of the proteins in
these fluids; and (iv) the difficulty to study low molecular
weight proteins and peptides expressed locally and better
reflecting the pathogenesis of the organ involvement. Until
now, the proteomic studies have identified new interesting
proteins in biological fluids from patients with auto-
immune-rheumatologic disorders, opening new scenario on
both pathogenesis of these diseases and their clinical
management.
Future studies should be designed on a large number of
patients and with standardized protocols most likely
through an international network involving specialized
clinical and proteomic centers working together in the
development of tools suitable for routine clinical use and for
progress in knowledge of the pathogenesis of these invali-
dating, chronic disorders.
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